Guggenheim Names Top Stock Pick in Biotech Sector

Guggenheim reiterated its Buy rating and $175 price target on Abivax, citing €1.2 billion of pro-forma cash that extends the company’s operating runway into Q4 2029. Positive pre-NDA regulatory interactions for obefazimod and forthcoming long-term Phase IIb data support the firm's outlook, which projects roughly $5 billion in combined global peak sales across ulcerative colitis and Crohn’s disease. Abivax estimates obefazimod could capture about 20% of a U.S. ulcerative colitis market projected to reach $15 billion by 2032.

Analysis

ABVX’s investable value is concentrated in regulatory execution and eventual differentiation versus entrenched UC franchises, not in the distant combination program. A clean pre-submission dialogue lowers the probability of a filing-format delay, but it does not validate approvability, labeling, or payer access; those variables will determine whether an oral entrant can take share from ABBV’s Rinvoq, BMY’s Zeposia, and biologic incumbents such as TAK’s Entyvio. The market is likely to reward additional durability and safety detail over the next 1-3 months, but only if subgroup data show consistency in biologic-experienced patients—the commercially valuable, hardest-to-treat cohort.

The cash position materially reduces near-term financing overhang, allowing ABVX to retain upside through the pivotal-to-commercial transition rather than raise equity into a binary regulatory window. Conversely, the very long lead time to combination development has little present fundamental value and should not be capitalized as a second product franchise. Management’s aspirational share assumptions imply substantial displacement of established therapies; a more realistic launch curve depends on formulary positioning, where a premium-price oral therapy may face step-edit restrictions even with a favorable safety profile.

Contrarian view: positive analyst reiterations and conference presentations can extend momentum, but this is not a new efficacy catalyst. If the stock rerates on perceived regulatory certainty before definitive approval and launch-access visibility, risk/reward deteriorates sharply because large-cap UC competitors can defend share through contracting. The key falsifiers are any FDA request that expands the safety package, weaker long-term discontinuation/remission durability than peers, or guidance indicating cash burn above the implied runway.

Key Decisions for Investors

• Maintain or initiate a modest long ABVX only as a 6-12 month regulatory-execution position; size it as a biotech binary rather than a core healthcare holding. Add only if upcoming long-term data demonstrate durable remission and discontinuation rates competitive with marketed advanced therapies, not merely favorable pooled averages.
• Use UEGW subgroup and long-term safety disclosures as a catalyst checkpoint over the next 1-3 months. Reduce exposure if biologic-experienced efficacy, steroid-free remission, or treatment persistence is materially weaker than the overall dataset; these metrics are more relevant to payer adoption than headline response rates.
• Do not underwrite material value for the combination program before candidate selection, partner economics, and human proof-of-concept are disclosed. Treat any share-price move driven primarily by preclinical combination language as a trimming opportunity rather than incremental fundamental upside.
• For relative-value healthcare books, pair a tactical ABVX long with a small short in broad biotech beta (XBI) rather than shorting ABBV, BMY, or TAK. The incumbents have diversified earnings and are unlikely to be materially impaired until ABVX demonstrates approval, formulary access, and real-world uptake.